Clinical Trial Update: Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections [Phase 3]

View source ↗

Summary

Phase 3 trial comparing intravenous CXA-201 to intravenous Meropenem in complicated intraabdominal infection has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Intraabdominal Infection

Drugs mentioned

• CXA-201
• Meropenem (Meropenem)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Complicated Intra-abdominal Infection | Phase 3 | Status: COMPLETED | Results posted: 2015-01-15